Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,921.50    0.00 (0.00%)
Bid:
1,887.50
Ask:
1,999.00
Spread: 111.50 (5.907%)
Market Cap: £77.03b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Amendment - Director/PDMR Shareholding

16 Apr 2024 14:11

RNS Number : 8437K
GSK PLC
16 April 2024
Β 

The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 15 April 2024 at 15:30 under RNS No 6703K:

- A typographical correction to the share price for the transaction shown in the table below.

All other details to the original announcement remain unchanged.

The amended table is shown below.

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Amendment

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ΒΌ pence each ('Ordinary Shares')

Β 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA

Β 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Β£16.3860

19

d)

Aggregated information

Β 

N/A (single transaction)

Β 

Β 

Aggregated volume Price

e)

Date of the transaction

2024-04-12

f)

Place of the transaction

Β 

London Stock Exchange (XLON)

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHXQLFFZZLBBBD
Date   Source Headline
20th Dec 20247:00 amRNSHeadline results from phase III FIRST trial
16th Dec 20247:11 amRNSJemperli receives US FDA breakthrough designation
16th Dec 20247:05 amRNSEMA grants PRIME Designation for GSK’227
16th Dec 20247:00 amRNSJemperli receives positive CHMP opinion
12th Dec 20243:30 pmRNSDirector/PDMR Shareholding
9th Dec 20246:29 pmRNSOverall survival data presented for Blenrep
9th Dec 20247:05 amRNSBlenrep combination China filing acceptance
9th Dec 20247:00 amRNSNucala COPD submission accepted by US FDA
5th Dec 20247:00 amRNSZhifei China collaboration revised and extended
2nd Dec 20243:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20243:00 pmRNSTotal Voting Rights
27th Nov 20247:00 amRNSGSK liquid meningitis vaccine authorised in EU
25th Nov 20247:00 amRNSBlenrep combinations accepted for US FDA review
22nd Nov 20247:00 amRNSJapan approves first RSV vaccine for adults 50-59
19th Nov 20243:30 pmRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSGLISTEN Trial of Linerixibat Meets Endpoint
14th Nov 20247:00 amRNSGSK announces overall survival results for Blenrep
13th Nov 20243:00 pmRNSBlock listing Interim Review
12th Nov 20243:30 pmRNSDirector/PDMR Shareholding
11th Nov 20243:01 pmRNSGSK publishes provisional 2025 dividend dates
1st Nov 20243:00 pmRNSTotal Voting Rights
30th Oct 20242:29 pmRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNS3rd Quarter Results
24th Oct 20247:00 amRNSNew positive Arexvy data in younger adults at risk
17th Oct 20243:30 pmRNSDirector/PDMR Shareholding
16th Oct 20244:09 pmRNSDirector/PDMR Shareholding
16th Oct 20247:00 amRNSFDA accepts new drug application for gepotidacin
14th Oct 20243:30 pmRNSDirector/PDMR Shareholding
14th Oct 20247:00 amRNSPositive results of ANCHOR trials of depemokimab
11th Oct 20243:33 pmRNSDirector/PDMR Shareholding
10th Oct 20243:30 pmRNSDirector/PDMR Shareholding
9th Oct 20245:48 pmRNSZantac (ranitidine) litigation settlements
8th Oct 202411:45 amRNSPositive efficacy data of Arexvy over 3 seasons
1st Oct 20243:00 pmRNSTotal Voting Rights
24th Sep 20243:30 pmRNSDirector/PDMR Shareholding
24th Sep 20247:00 amRNSPositive EU opinion for GSK liquid Menveo vaccine
18th Sep 20241:20 pmRNSStatement: Zantac (ranitidine) litigation
17th Sep 20247:00 amRNSJapan Filing Acceptance: Blenrep Multiple Myeloma
13th Sep 20247:00 amRNSChina Breakthrough Therapy Designation for Blenrep
12th Sep 20243:30 pmRNSDirector/PDMR Shareholding
12th Sep 20247:00 amRNSPositive mRNA flu vaccine Phase II headline data
11th Sep 20245:27 pmRNSStatement: Zantac (ranitidine) litigation
11th Sep 20243:30 pmRNSChange of Registered Office
11th Sep 20247:00 amRNSUpdate on phase I/II therapeutic HSV vaccine trial
9th Sep 20242:30 pmRNSDepemokimab late-breaking data presented at ERS
6th Sep 20243:30 pmRNSDirector/PDMR Shareholding
6th Sep 20247:00 amRNSPositive Phase III results for Nucala in COPD
2nd Sep 20243:00 pmRNSTotal Voting Rights
29th Aug 20247:00 amRNSEMA approval on Arexvy for 50-59 at risk
28th Aug 20247:10 amRNSSENKU Designation for Bepirovirsen in Japan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.